BACKGROUND: The relationships of inflammation, immune activation, and immunosenescence markers with functional impairment in aging human immunodeficiency virus type 1 (HIV-1)-infected persons are unknown. METHODS: HIV-infected persons who were aged 45-65 years, had a plasma HIV-1 RNA load of <48 copies/mL, and were receiving antiretroviral therapy underwent standardized functional testing. In a nested case-control analysis, low-functioning cases were matched (1:1-2) by age, sex, and HIV-1 diagnosis date to high-functioning controls. Markers of inflammation, T-cell activation, microbial translocation, immunosenescence, and immune recovery were used to estimate functional status in conditional logistic regression. Primary analyses were adjusted for CD4(+) T-cell count, smoking, and hepatitis. RESULTS: Thirty-one low-functioning cases were compared to 49 high-functioning controls. After statistical adjustment, lower proportions of CD4(+) T cells and higher proportion of CD8(+) T cells, higher CD38/HLA-DR expression on CD8(+) T cells, and higher interleukin-6 were associated with a significantly greater odds of low functional status (odds ratio, ≥ 1.1 for all analyses; P ≤ .03). Other inflammatory, senescence, and microbial translocation markers were not significantly different (P ≥ .11 for all analyses) between low-functioning and high-functioning groups. CONCLUSIONS: Functional impairment during successful antiretroviral therapy was associated with higher CD8(+) T-cell activation and interleukin 6 levels. Interventions to decrease immune activation and inflammation should be evaluated for their effects on physical function and frailty.
BACKGROUND: The relationships of inflammation, immune activation, and immunosenescence markers with functional impairment in aging human immunodeficiency virus type 1 (HIV-1)-infectedpersons are unknown. METHODS:HIV-infectedpersons who were aged 45-65 years, had a plasma HIV-1 RNA load of <48 copies/mL, and were receiving antiretroviral therapy underwent standardized functional testing. In a nested case-control analysis, low-functioning cases were matched (1:1-2) by age, sex, and HIV-1 diagnosis date to high-functioning controls. Markers of inflammation, T-cell activation, microbial translocation, immunosenescence, and immune recovery were used to estimate functional status in conditional logistic regression. Primary analyses were adjusted for CD4(+) T-cell count, smoking, and hepatitis. RESULTS: Thirty-one low-functioning cases were compared to 49 high-functioning controls. After statistical adjustment, lower proportions of CD4(+) T cells and higher proportion of CD8(+) T cells, higher CD38/HLA-DR expression on CD8(+) T cells, and higher interleukin-6 were associated with a significantly greater odds of low functional status (odds ratio, ≥ 1.1 for all analyses; P ≤ .03). Other inflammatory, senescence, and microbial translocation markers were not significantly different (P ≥ .11 for all analyses) between low-functioning and high-functioning groups. CONCLUSIONS: Functional impairment during successful antiretroviral therapy was associated with higher CD8(+) T-cell activation and interleukin 6 levels. Interventions to decrease immune activation and inflammation should be evaluated for their effects on physical function and frailty.
Authors: Robert C Kalayjian; Rhoderick N Machekano; Nesrine Rizk; Gregory K Robbins; Rajesh T Gandhi; Benigno A Rodriguez; Richard B Pollard; Michael M Lederman; Alan Landay Journal: J Infect Dis Date: 2010-06-15 Impact factor: 5.226
Authors: Karen Anne Mather; Anthony Francis Jorm; Ruth Adeline Parslow; Helen Christensen Journal: J Gerontol A Biol Sci Med Sci Date: 2010-10-28 Impact factor: 6.053
Authors: Wei Jiang; Michael M Lederman; Peter Hunt; Scott F Sieg; Kathryn Haley; Benigno Rodriguez; Alan Landay; Jeffrey Martin; Elizabeth Sinclair; Ava I Asher; Steven G Deeks; Daniel C Douek; Jason M Brenchley Journal: J Infect Dis Date: 2009-04-15 Impact factor: 5.226
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Rosa Ana Risques; Konstantin G Arbeev; Anatoli I Yashin; Svetlana V Ukraintseva; George M Martin; Peter S Rabinovitch; Junko Oshima Journal: J Am Geriatr Soc Date: 2010-06-23 Impact factor: 5.562
Authors: Krisann K Oursler; Joseph L Goulet; Stephen Crystal; Amy C Justice; Kristina Crothers; Adeel A Butt; Maria C Rodriguez-Barradas; Knachelle Favors; David Leaf; Leslie I Katzel; John D Sorkin Journal: AIDS Patient Care STDS Date: 2011-01 Impact factor: 5.078
Authors: Nur F Onen; Abayomi Agbebi; Enbal Shacham; Kate E Stamm; Alev R Onen; E Turner Overton Journal: J Infect Date: 2009-08-23 Impact factor: 6.072
Authors: Arpi S Terzian; Susan Holman; Niyati Nathwani; Esther Robison; Kathleen Weber; Mary Young; Ruth M Greenblatt; Stephen J Gange Journal: J Womens Health (Larchmt) Date: 2009-12 Impact factor: 2.681
Authors: Emily C Liang; Lindsay Sceats; Nicholas L Bayless; Dara M Strauss-Albee; Jessica Kubo; Philip M Grant; David Furman; Manisha Desai; David A Katzenstein; Mark M Davis; Andrew R Zolopa; Catherine A Blish Journal: J Virol Date: 2014-05-21 Impact factor: 5.103
Authors: Damani A Piggott; Ravi Varadhan; Shruti H Mehta; Todd T Brown; Huifen Li; Jeremy D Walston; Sean X Leng; Gregory D Kirk Journal: J Gerontol A Biol Sci Med Sci Date: 2015-09-18 Impact factor: 6.053
Authors: Meredith Greene; Kenneth Covinsky; Jacquie Astemborski; Damani A Piggott; Todd Brown; Sean Leng; Noya Galai; Shruti H Mehta; Jack Guralnik; Kushang V Patel; Gregory D Kirk Journal: AIDS Date: 2014-11-28 Impact factor: 4.177
Authors: M Nasi; S De Biasi; L Gibellini; E Bianchini; S Pecorini; V Bacca; G Guaraldi; C Mussini; M Pinti; A Cossarizza Journal: Clin Exp Immunol Date: 2016-08-09 Impact factor: 4.330